<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230906141001&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20230906141001&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Wed, 06 Sep 2023 18:10:01 +0000</lastbuilddate>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Adult With Unrepaired Single-Ventricle Defect</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672288/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2748. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672288/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672288</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2748>10.1001/jamacardio.2023.2748</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672288</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>David Gregg</dc:creator>
<dc:creator>Andrew D Vogel</dc:creator>
<dc:creator>Taufiek K Rajab</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Adult With Unrepaired Single-Ventricle Defect</dc:title>
<dc:identifier>pmid:37672288</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2748</dc:identifier>
</item>
<item>
<title>Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672268/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2808. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Valsartan has shown promise in attenuating cardiac remodeling in patients with early-stage sarcomeric hypertrophic cardiomyopathy (HCM). Genetic testing can identify individuals at risk of HCM in a subclinical stage who could benefit from therapies that prevent disease progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To explore the potential for valsartan to modify disease development, and to characterize short-term phenotypic progression in subclinical HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The multicenter, double-blind, placebo-controlled Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) randomized clinical trial was conducted from April 2014 to July 2019 at 17 sites in 4 countries (Brazil, Canada, Denmark, and the US), with 2 years of follow-up. The prespecified exploratory VANISH cohort studied here included sarcomere variant carriers with subclinical HCM and early phenotypic manifestations (reduced E' velocity, electrocardiographic abnormalities, or an increased left ventricular [LV] wall thickness [LVWT] to cavity diameter ratio) but no LV hypertrophy (LVH). Data were analyzed between March and December 2022.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Treatment with placebo or valsartan (80 mg/d for children weighing &lt;35 kg, 160 mg/d for children weighing ≥35 kg, or 320 mg/d for adults aged ≥18 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite z score incorporating changes in 9 parameters of cardiac remodeling (LV cavity volume, LVWT, and LV mass; left atrial [LA] volume; E' velocity and S' velocity; and serum troponin and N-terminal prohormone of brain natriuretic peptide levels).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: This study included 34 participants, with a mean (SD) age of 16 (5) years (all were White). A total of 18 participants (8 female [44%] and 10 male [56%]) were randomized to valsartan and 16 (9 female [56%] and 7 male [44%]) were randomized to placebo. No statistically significant effects of valsartan on cardiac remodeling were detected (mean change in composite z score compared with placebo: -0.01 [95% CI, -0.29 to 0.26]; P = .92). Overall, 2-year phenotypic progression was modest, with only a mild increase in LA volume detected (increased by 3.5 mL/m2 [95% CI, 1.4-6.0 mL/m2]; P = .002). Nine participants (26%) had increased LVWT, including 6 (18%) who developed clinically overt HCM. Baseline LA volume index (LAVI; 35 vs 28 mL/m2; P = .01) and average interventricular septum thickness (8.5 vs 7.0 mm; P = .009) were higher in participants who developed HCM.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this exploratory cohort, valsartan was not proven to slow progression of subclinical HCM. Minimal changes in markers of cardiac remodeling were observed, although nearly one-fifth of patients developed clinically overt HCM. Transition to disease was associated with greater baseline interventricular septum thickness and LAVI. These findings highlight the importance of following sarcomere variant carriers longitudinally and the critical need to improve understanding of factors that drive disease penetrance and progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01912534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672268/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672268</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2808>10.1001/jamacardio.2023.2808</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672268</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Christoffer Rasmus Vissing</dc:creator>
<dc:creator>Anna Axelsson Raja</dc:creator>
<dc:creator>Sharlene M Day</dc:creator>
<dc:creator>Mark W Russell</dc:creator>
<dc:creator>Kenneth Zahka</dc:creator>
<dc:creator>Harry M Lever</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>Steven D Colan</dc:creator>
<dc:creator>Renee Margossian</dc:creator>
<dc:creator>Anne M Murphy</dc:creator>
<dc:creator>Charles Canter</dc:creator>
<dc:creator>Richard G Bach</dc:creator>
<dc:creator>Matthew T Wheeler</dc:creator>
<dc:creator>Joseph W Rossano</dc:creator>
<dc:creator>Anjali T Owens</dc:creator>
<dc:creator>Lee Benson</dc:creator>
<dc:creator>Luisa Mestroni</dc:creator>
<dc:creator>Matthew R G Taylor</dc:creator>
<dc:creator>Amit R Patel</dc:creator>
<dc:creator>Ivan Wilmot</dc:creator>
<dc:creator>Philip Thrush</dc:creator>
<dc:creator>Jonathan H Soslow</dc:creator>
<dc:creator>Jason R Becker</dc:creator>
<dc:creator>Christine E Seidman</dc:creator>
<dc:creator>Neal K Lakdawala</dc:creator>
<dc:creator>Allison L Cirino</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Calum A MacRae</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Henning Bundgaard</dc:creator>
<dc:creator>E John Orav</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:creator>Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Cardiac Remodeling in Subclinical Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37672268</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2808</dc:identifier>
</item>
<item>
<title>A Tribute to William C. Roberts, MD, 1932-2023</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672267/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2853. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672267/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672267</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2853>10.1001/jamacardio.2023.2853</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672267</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Patrick T O'Gara</dc:creator>
<dc:creator>Robert O Bonow</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Tribute to William C. Roberts, MD, 1932-2023</dc:title>
<dc:identifier>pmid:37672267</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2853</dc:identifier>
</item>
<item>
<title>Linking Kidney Vessel Scarring to Cardiovascular Risk</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672266/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2752. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672266/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672266</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2752>10.1001/jamacardio.2023.2752</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672266</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Thibaut d'Izarny-Gargas</dc:creator>
<dc:creator>Alexandre Karras</dc:creator>
<dc:creator>Jean-Paul Duong-Van-Huyen</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Linking Kidney Vessel Scarring to Cardiovascular Risk</dc:title>
<dc:identifier>pmid:37672266</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2752</dc:identifier>
</item>
<item>
<title>Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672260/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: In a national sample of US adults, insulin resistance was inversely associated with NT-proBNP, even after rigorously accounting for multiple measures of fat mass and lean mass. These results suggest that the mechanisms linking NT-proBNP to insulin resistance are partially independent of excess adiposity and may be associated with hyperinsulinemia.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2758. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: It is unclear to what extent insulin resistance is associated with N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the general population after accounting for body composition.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To characterize the association of insulin resistance with NT-proBNP independently of measures of body composition in US adults.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In a cross-sectional design, data on participants aged 20 years or older were obtained from the 1999-2004 National Health and Nutrition Examination Survey with measures of NT-pro-BNP, body mass index (BMI), and dual energy x-ray absorptiometry (DEXA)-derived measures of body composition (fat and lean masses). Linear and logistic regression was used to characterize the associations of measures of body mass and composition (BMI, waist circumference, fat mass, and lean mass) with NT-proBNP, adjusting for cardiovascular risk factors. Linear regression was used to characterize the associations of homeostasis model assessment of insulin resistance [HOMA-IR] and NT-proBNP after adjusting for cardiovascular risk factors and body composition measures. The quantitative insulin sensitivity check index [QUICKI], triglyceride-glucose index [TyG index], insulin to glucose ratio [IGR], fasting insulin, and homeostasis model assessment of β-cell function (HOMA-β) were also examined. Data for this study were analyzed from August 10, 2022, to June 30, 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Adjusted changes in NT-proBNP by insulin resistance levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 4038 adults without diabetes or cardiovascular disease were included (mean [SD] age, 44 years; 51.2% female; and 74.3% White). In sex-specific analyses, insulin resistance measures were inversely associated with NT-pro-BNP. After adjustment including cardiovascular risk factors, BMI, waist circumference, and DEXA-derived fat mass and lean mass, the percent change in NT-proBNP associated with an SD increase in HOMA-IR was -16.84% (95% CI, -21.23% to -12.21%) in women and -19.04% (95% CI, -24.14 to -13.59) in men. Similar associations were observed for other indices of insulin resistance, including QUICKI (women: 17.27; 95% CI, 10.92-23.99 vs men: 22.17; 95% CI, 15.27 to 29.48), TyG index women: -11.47; 95% CI, -16.12 to -6.57 vs men: -15.81; 95% CI, -20.40 to -10.95), IGR women: -15.15; 95% CI, -19.35 to -10.74 vs men: -16.61; 95% CI, -21.63 to -11.26), and fasting insulin (women: -16.32; 95% CI, -20.63 to -11.78 vs men: -18.22; 95% CI, -23.30 to -12.79), as well as HOMA-β (women: -10.71; 95% CI, -14.71 to -6.52 vs men: -11.72; 95% CI, -16.35 to -6.85).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In a national sample of US adults, insulin resistance was inversely associated with NT-proBNP, even after rigorously accounting for multiple measures of fat mass and lean mass. These results suggest that the mechanisms linking NT-proBNP to insulin resistance are partially independent of excess adiposity and may be associated with hyperinsulinemia.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672260/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672260</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2758>10.1001/jamacardio.2023.2758</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672260</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Justin B Echouffo-Tcheugui</dc:creator>
<dc:creator>Sui Zhang</dc:creator>
<dc:creator>John W McEvoy</dc:creator>
<dc:creator>Stephen P Juraschek</dc:creator>
<dc:creator>Michael Fang</dc:creator>
<dc:creator>Chiadi E Ndumele</dc:creator>
<dc:creator>Robert H Christenson</dc:creator>
<dc:creator>Elizabeth Selvin</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Insulin Resistance and N-Terminal Pro-B-Type Natriuretic Peptide Among Healthy Adults</dc:title>
<dc:identifier>pmid:37672260</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2758</dc:identifier>
</item>
<item>
<title>Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37672259/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 6. doi: 10.1001/jamacardio.2023.2755. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37672259/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37672259</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.2755>10.1001/jamacardio.2023.2755</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37672259</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Leo Buckley</dc:creator>
<dc:creator>Ragnar Palsson</dc:creator>
<dc:creator>Sushrut S Waikar</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Linking Kidney Vessel Scarring to Cardiovascular Risk-Reply</dc:title>
<dc:identifier>pmid:37672259</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.2755</dc:identifier>
</item>
<item>
<title>Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37671551/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity. The cost-effectiveness of vericiguat was driven by the projected incremental life expectancy among patients in the lowest 3 quartiles of NT-proBNP.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 6. doi: 10.1161/CIRCULATIONAHA.122.063602. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The VICTORIA trial (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) demonstrated that, in patients with high-risk heart failure, vericiguat reduced the primary composite outcome of cardiovascular death or heart failure hospitalization relative to placebo. The hazard ratio for all-cause mortality was 0.95 (95% CI, 0.84-1.07). In a prespecified analysis, treatment effects varied substantially as a function of baseline NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels, with survival benefit for vericiguat in the lower NT-proBNP quartiles (hazard ratio, 0.82 [95% CI, 0.69-0.97]) and no benefit in the highest NT-proBNP quartile (hazard ratio, 1.14 [95% CI, 0.95-1.38]). An economic analysis was a major secondary objective of the VICTORIA research program.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Medical resource use data were collected for all VICTORIA patients (N=5050). Costs were estimated by applying externally derived US cost weights to resource use counts. Life expectancy was projected from patient-level empirical trial survival results with the use of age-based survival modeling methods. Quality-of-life adjustments were based on prospectively collected EQ-5D-based utilities. The primary outcome was the incremental cost-effectiveness ratio, comparing vericiguat with placebo, assessed from the US health care sector perspective over a lifetime horizon. Cost-effectiveness was estimated using the total VICTORIA cohort, both with and without interaction between treatment and baseline NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Life expectancy modeling results varied according to whether the observed heterogeneity of treatment effect by baseline NT-proBNP values was incorporated into the modeling. Including the interaction term, the vericiguat arm had an estimated quality-adjusted life expectancy of 4.56 quality-adjusted life-years (QALYs) compared with 4.13 QALYs for placebo (incremental discounted QALY, 0.43). Without the treatment heterogeneity/interaction term, vericiguat had 4.50 QALYs compared with 4.33 QALYs for placebo (incremental discounted QALY, 0.17). Incremental discounted costs (vericiguat minus placebo) were $28 546 with the treatment interaction and $20 948 without it. Corresponding incremental cost-effectiveness ratios were $66 509 per QALY allowing for treatment heterogeneity and $124 512 without heterogeneity.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Vericiguat use in the VICTORIA trial met criteria for intermediate value, but the incremental cost-effectiveness ratio estimates were sensitive to whether the analysis accounted for observed NT-proBNP treatment effect heterogeneity. The cost-effectiveness of vericiguat was driven by the projected incremental life expectancy among patients in the lowest 3 quartiles of NT-proBNP.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">REGISTRATION: URL: https://www.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICALTRIALS: gov; Unique identifier: NCT02861534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37671551/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37671551</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.122.063602>10.1161/CIRCULATIONAHA.122.063602</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37671551</guid>
<pubDate>Wed, 06 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Derek S Chew</dc:creator>
<dc:creator>Yanhong Li</dc:creator>
<dc:creator>Robert Bigelow</dc:creator>
<dc:creator>Patricia A Cowper</dc:creator>
<dc:creator>Kevin J Anstrom</dc:creator>
<dc:creator>Melanie R Daniels</dc:creator>
<dc:creator>Linda Davidson-Ray</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Christopher M O'Connor</dc:creator>
<dc:creator>Paul W Armstrong</dc:creator>
<dc:creator>Daniel B Mark</dc:creator>
<dc:creator>VICTORIA Study Group</dc:creator>
<dc:date>2023-09-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37671551</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.122.063602</dc:identifier>
</item>
<item>
<title>Reducing radiation to the heart in breast cancer: is that all that matters?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670408/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad528. doi: 10.1093/eurheartj/ehad528. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670408/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670408</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad528>10.1093/eurheartj/ehad528</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670408</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Marianne Aznar</dc:creator>
<dc:creator>Anju Nohria</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Reducing radiation to the heart in breast cancer: is that all that matters?</dc:title>
<dc:identifier>pmid:37670408</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad528</dc:identifier>
</item>
<item>
<title>Artificial intelligence and innovation of clinical care: the need for evidence in the real world</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad553. doi: 10.1093/eurheartj/ehad553. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670406</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad553>10.1093/eurheartj/ehad553</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670406</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Andrew J Fletcher</dc:creator>
<dc:creator>Casey L Johnson</dc:creator>
<dc:creator>Paul Leeson</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Artificial intelligence and innovation of clinical care: the need for evidence in the real world</dc:title>
<dc:identifier>pmid:37670406</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad553</dc:identifier>
</item>
<item>
<title>The stroke enigma: decoding the sex risk factor in atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670405/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad531. doi: 10.1093/eurheartj/ehad531. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670405/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670405</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad531>10.1093/eurheartj/ehad531</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670405</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Melissa E Middeldorp</dc:creator>
<dc:creator>Roopinder K Sandhu</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The stroke enigma: decoding the sex risk factor in atrial fibrillation</dc:title>
<dc:identifier>pmid:37670405</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad531</dc:identifier>
</item>
<item>
<title>Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670404/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad525. doi: 10.1093/eurheartj/ehad525. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670404/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670404</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad525>10.1093/eurheartj/ehad525</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670404</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Christiane E Angermann</dc:creator>
<dc:creator>Georg Ertl</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Remote heart failure management guided by pulmonary artery pressure home monitoring: rewriting the future?</dc:title>
<dc:identifier>pmid:37670404</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad525</dc:identifier>
</item>
<item>
<title>Hospitalization for heart failure requires a PROMPT response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670351/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 6:ehad444. doi: 10.1093/eurheartj/ehad444. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670351/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670351</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad444>10.1093/eurheartj/ehad444</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670351</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Nicholas K Brownell</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hospitalization for heart failure requires a PROMPT response</dc:title>
<dc:identifier>pmid:37670351</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad444</dc:identifier>
</item>
<item>
<title>New insights into OCT-guided PCI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37670011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Sep 5. doi: 10.1038/s41569-023-00930-x. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37670011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37670011</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00930-x>10.1038/s41569-023-00930-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37670011</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>New insights into OCT-guided PCI</dc:title>
<dc:identifier>pmid:37670011</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00930-x</dc:identifier>
</item>
<item>
<title>Corticotropin-releasing hormone signaling from prefrontal cortex to lateral septum suppresses interaction with familiar mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669667/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>Social preference, the decision to interact with one member of the same species over another, is critical to optimize social interactions. Thus, adult rodents favor interacting with novel conspecifics over familiar ones, but whether this social preference stems from neural circuits facilitating interactions with novel individuals or suppressing interactions with familiar ones remains unknown. Here, we identify neurons in the infra-limbic area (ILA) of the mouse prefrontal cortex that express the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 29:S0092-8674(23)00864-4. doi: 10.1016/j.cell.2023.08.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Social preference, the decision to interact with one member of the same species over another, is critical to optimize social interactions. Thus, adult rodents favor interacting with novel conspecifics over familiar ones, but whether this social preference stems from neural circuits facilitating interactions with novel individuals or suppressing interactions with familiar ones remains unknown. Here, we identify neurons in the infra-limbic area (ILA) of the mouse prefrontal cortex that express the neuropeptide corticotropin-releasing hormone (CRH) and project to the dorsal region of the rostral lateral septum (rLS). We show how release of CRH during familiar encounters disinhibits rLS neurons, thereby suppressing social interactions with familiar mice and contributing to social novelty preference. We further demonstrate how the maturation of CRH expression in ILA during the first 2 post-natal weeks enables the developmental shift from a preference for littermates in juveniles to a preference for novel mice in adults.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669667/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669667</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.010>10.1016/j.cell.2023.08.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669667</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Noelia Sofia de León Reyes</dc:creator>
<dc:creator>Paula Sierra Díaz</dc:creator>
<dc:creator>Ramon Nogueira</dc:creator>
<dc:creator>Antonia Ruiz-Pino</dc:creator>
<dc:creator>Yuki Nomura</dc:creator>
<dc:creator>Christopher A de Solis</dc:creator>
<dc:creator>Jay Schulkin</dc:creator>
<dc:creator>Arun Asok</dc:creator>
<dc:creator>Felix Leroy</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Corticotropin-releasing hormone signaling from prefrontal cortex to lateral septum suppresses interaction with familiar mice</dc:title>
<dc:identifier>pmid:37669667</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.010</dc:identifier>
</item>
<item>
<title>Retraction Notice to: A Ligand-Gated Association between Cytoplasmic Domains of UNC5 and DCC Family Receptors Converts Netrin-Induced Growth Cone Attraction to Repulsion</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669666/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 30:S0092-8674(23)00913-3. doi: 10.1016/j.cell.2023.08.024. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669666/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669666</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.024>10.1016/j.cell.2023.08.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669666</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kyonsoo Hong</dc:creator>
<dc:creator>Lindsay Hinck</dc:creator>
<dc:creator>Makoto Nishiyama</dc:creator>
<dc:creator>Mu-Ming Poo</dc:creator>
<dc:creator>Marc Tessier-Lavigne</dc:creator>
<dc:creator>Elke Stein</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Retraction Notice to: A Ligand-Gated Association between Cytoplasmic Domains of UNC5 and DCC Family Receptors Converts Netrin-Induced Growth Cone Attraction to Repulsion</dc:title>
<dc:identifier>pmid:37669666</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.024</dc:identifier>
</item>
<item>
<title>Airborne transmission of human-isolated avian H3N8 influenza virus between ferrets</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669665/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>H3N8 avian influenza viruses (AIVs) in China caused two confirmed human infections in 2022, followed by a fatal case reported in 2023. H3N8 viruses are widespread in chicken flocks; however, the zoonotic features of H3N8 viruses are poorly understood. Here, we demonstrate that H3N8 viruses were able to infect and replicate efficiently in organotypic normal human bronchial epithelial (NHBE) cells and lung epithelial (Calu-3) cells. Human isolates of H3N8 virus were more virulent and caused severe...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Aug 24:S0092-8674(23)00891-7. doi: 10.1016/j.cell.2023.08.011. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">H3N8 avian influenza viruses (AIVs) in China caused two confirmed human infections in 2022, followed by a fatal case reported in 2023. H3N8 viruses are widespread in chicken flocks; however, the zoonotic features of H3N8 viruses are poorly understood. Here, we demonstrate that H3N8 viruses were able to infect and replicate efficiently in organotypic normal human bronchial epithelial (NHBE) cells and lung epithelial (Calu-3) cells. Human isolates of H3N8 virus were more virulent and caused severe pathology in mice and ferrets, relative to chicken isolates. Importantly, H3N8 virus isolated from a patient with severe pneumonia was transmissible between ferrets through respiratory droplets; it had acquired human-receptor-binding preference and amino acid substitution PB2-E627K necessary for airborne transmission. Human populations, even when vaccinated against human H3N2 virus, appear immunologically naive to emerging mammalian-adapted H3N8 AIVs and could be vulnerable to infection at epidemic or pandemic proportion.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669665/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669665</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.011>10.1016/j.cell.2023.08.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669665</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Honglei Sun</dc:creator>
<dc:creator>Han Li</dc:creator>
<dc:creator>Qi Tong</dc:creator>
<dc:creator>Qiqi Han</dc:creator>
<dc:creator>Jiyu Liu</dc:creator>
<dc:creator>Haili Yu</dc:creator>
<dc:creator>Hao Song</dc:creator>
<dc:creator>Jianxun Qi</dc:creator>
<dc:creator>Jiaqi Li</dc:creator>
<dc:creator>Jizhe Yang</dc:creator>
<dc:creator>Riguo Lan</dc:creator>
<dc:creator>Guojing Deng</dc:creator>
<dc:creator>Haoyu Chang</dc:creator>
<dc:creator>Yajin Qu</dc:creator>
<dc:creator>Juan Pu</dc:creator>
<dc:creator>Yipeng Sun</dc:creator>
<dc:creator>Yu Lan</dc:creator>
<dc:creator>Dayan Wang</dc:creator>
<dc:creator>Yi Shi</dc:creator>
<dc:creator>William J Liu</dc:creator>
<dc:creator>Kin-Chow Chang</dc:creator>
<dc:creator>George F Gao</dc:creator>
<dc:creator>Jinhua Liu</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Airborne transmission of human-isolated avian H3N8 influenza virus between ferrets</dc:title>
<dc:identifier>pmid:37669665</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.011</dc:identifier>
</item>
<item>
<title>Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669360/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 5;148(10):819-821. doi: 10.1161/CIRCULATIONAHA.123.065789. Epub 2023 Sep 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669360/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669360</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065789>10.1161/CIRCULATIONAHA.123.065789</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669360</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Michael P Ayers</dc:creator>
<dc:creator>Christopher M Kramer</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Imaging Myofibrillar Disarray and Microvascular Dysfunction in Hypertrophic Cardiomyopathy: Novel Imaging Biomarkers for a New Era in Therapeutics</dc:title>
<dc:identifier>pmid:37669360</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065789</dc:identifier>
</item>
<item>
<title>Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669359/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 5;148(10):855-856. doi: 10.1161/CIRCULATIONAHA.123.065539. Epub 2023 Sep 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669359/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669359</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065539>10.1161/CIRCULATIONAHA.123.065539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669359</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Hua Zhu</dc:creator>
<dc:creator>Yu-Chen Song</dc:creator>
<dc:creator>Peng-Zhou Hang</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Zhu et al Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure"</dc:title>
<dc:identifier>pmid:37669359</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065539</dc:identifier>
</item>
<item>
<title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669358/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 5;148(10):848-851. doi: 10.1161/CIRCULATIONAHA.123.066537. Epub 2023 Sep 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669358/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669358</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066537>10.1161/CIRCULATIONAHA.123.066537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669358</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Highlights From the &lt;em>;Circulation&lt;/em>; Family of Journals</dc:title>
<dc:identifier>pmid:37669358</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066537</dc:identifier>
</item>
<item>
<title>Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669357/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 5;148(10):857-858. doi: 10.1161/CIRCULATIONAHA.123.065884. Epub 2023 Sep 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669357/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669357</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065884>10.1161/CIRCULATIONAHA.123.065884</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669357</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jan Magnus Aronsen</dc:creator>
<dc:creator>Jonas Skogestad</dc:creator>
<dc:creator>Ingrid Albert</dc:creator>
<dc:creator>Arne Olav Melleby</dc:creator>
<dc:creator>Cathrine R Carlson</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Response by Aronsen et al to Letter Regarding Article, "Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure"</dc:title>
<dc:identifier>pmid:37669357</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065884</dc:identifier>
</item>
<item>
<title>The Epidemic and Data-Free Zone of Nonsustained Ventricular Tachycardia: An Unintended Consequence of Digital Monitoring and a Path Forward</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37669356/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230906141001&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 5;148(10):805-807. doi: 10.1161/CIRCULATIONAHA.123.066049. Epub 2023 Sep 5.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37669356/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230906141001&v=2.17.9.post6+86293ac">37669356</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066049>10.1161/CIRCULATIONAHA.123.066049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37669356</guid>
<pubDate>Tue, 05 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Krishna Pundi</dc:creator>
<dc:creator>Gregory M Marcus</dc:creator>
<dc:creator>Mintu Turakhia</dc:creator>
<dc:date>2023-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Epidemic and Data-Free Zone of Nonsustained Ventricular Tachycardia: An Unintended Consequence of Digital Monitoring and a Path Forward</dc:title>
<dc:identifier>pmid:37669356</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066049</dc:identifier>
</item>





























</channel>
</rss>